{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:51:41Z","timestamp":1794588701314,"version":"4.9.1"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"24","funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["RSG-16- 117-01-LIB"],"award-info":[{"award-number":["RSG-16- 117-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["NCI-5K23CA178083"],"award-info":[{"award-number":["NCI-5K23CA178083"]}]},{"name":"National Cancer Institute","award":["K08CA252642"],"award-info":[{"award-number":["K08CA252642"]}]},{"name":"National Cancer Institute","award":["NCI-F31CA250320"],"award-info":[{"award-number":["NCI-F31CA250320"]}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL). These T cells can be activated and expanded for adoptive cell transfer (ACT), which has resulted in relatively high rates of clinical responses. Similarly, immune checkpoint inhibitors, specifically programmed cell death protein 1 (PD-1) blocking antibodies, augment antitumor immunity and increase the influx of T cells into tumors. Thus, we hypothesized that addition of PD-1 inhibition may improve the outcomes for patients undergoing ACT with TILs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with stage III\/IV metastatic melanoma with unresectable disease who were anti\u2013PD-1 treatment-na\u00efve were enrolled. TILs were generated in the presence of anti\u20134-1BB antibody in vitro and expanded for ACT. Patients in cohort 1 received TIL infusion followed by nivolumab. Patients in cohort 2 also received nivolumab prior to surgical harvest and during TIL production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 11 patients were enrolled, all of whom were evaluated for response, and nine completed ACT. Predominantly CD8+ TILs were successfully expanded from all ACT-treated patients and were tumor reactive in vitro. The trial met its safety endpoint, as there were no protocol-defined dose-limiting toxicity events. The objective response rate was 36%, and median progression-free survival was 5 months. Two nonresponders who developed new metastatic lesions were analyzed to determine potential mechanisms of therapeutic resistance, which included clonal divergence and intrinsic TIL dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Combination therapy with TILs and nivolumab was safe and feasible for patients with metastatic melanoma and provides important insights for future therapeutic developments in ACT with TILs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-22-2103","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T12:12:11Z","timestamp":1665403931000},"page":"5317-5329","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma"],"prefix":"10.1158","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-1619","authenticated-orcid":false,"given":"MacLean S.","family":"Hall","sequence":"first","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."},{"name":"2Cancer Biology PhD Program, University of South Florida, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-6785","authenticated-orcid":false,"given":"John E.","family":"Mullinax","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."},{"name":"3Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-2549","authenticated-orcid":false,"given":"Cheryl A.","family":"Cox","sequence":"additional","affiliation":[{"name":"4Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-1017","authenticated-orcid":false,"given":"Amy M.","family":"Hall","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3198-9264","authenticated-orcid":false,"given":"Matthew S.","family":"Beatty","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4529-7990","authenticated-orcid":false,"given":"Jamie","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-1134","authenticated-orcid":false,"given":"Patrick","family":"Innamarato","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-0360","authenticated-orcid":false,"given":"Luz","family":"Nagle","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-1662","authenticated-orcid":false,"given":"Holly","family":"Branthoover","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-8431","authenticated-orcid":false,"given":"Doris","family":"Wiener","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-7575","authenticated-orcid":false,"given":"Benjamin","family":"Schachner","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9061-8650","authenticated-orcid":false,"given":"Alberto J.","family":"Martinez","sequence":"additional","affiliation":[{"name":"4Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-5589","authenticated-orcid":false,"given":"Allison D.","family":"Richards","sequence":"additional","affiliation":[{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-1813","authenticated-orcid":false,"given":"Carolyn J.","family":"Rich","sequence":"additional","affiliation":[{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-7182","authenticated-orcid":false,"given":"Marjorie","family":"Col\u00f3n Col\u00f3n","sequence":"additional","affiliation":[{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4594-6601","authenticated-orcid":false,"given":"Michael J.","family":"Schell","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-0282","authenticated-orcid":false,"given":"Jamie K.","family":"Teer","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-4143","authenticated-orcid":false,"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-2957","authenticated-orcid":false,"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[{"name":"7Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-0516","authenticated-orcid":false,"given":"James J.","family":"Mul\u00e9","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-484X","authenticated-orcid":false,"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-3034","authenticated-orcid":false,"given":"Shari","family":"Pilon-Thomas","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-5898","authenticated-orcid":false,"given":"Amod A.","family":"Sarnaik","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."},{"name":"5Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"2025112507284084600_bib1","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib2","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025112507284084600_bib3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/1078-0432.CCR-14-1934","article-title":"Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"21","author":"Chacon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-10-2272","article-title":"Immunotherapy Task Force of the NCIIDSC. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy","volume":"17","author":"Weber","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ssu.2980050604","article-title":"Overview of interleukin-2 as an immunotherapeutic agent","volume":"5","author":"Chang","year":"1989","journal-title":"Semin Surg Oncol"},{"key":"2025112507284084600_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using High-dose bolus Interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"2025112507284084600_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00000658-198910000-00008","article-title":"Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients","volume":"210","author":"Rosenberg","year":"1989","journal-title":"Ann Surg"},{"key":"2025112507284084600_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2025112507284084600_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2025112507284084600_bib11","first-page":"91","article-title":"Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma","volume":"2","author":"Royal","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"2025112507284084600_bib12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.4049\/jimmunol.2000759","article-title":"Intratumoral Activation of 41BB costimulatory signals enhances CD8 T cell expansion and modulates Tumor-infiltrating myeloid cells","volume":"205","author":"Innamarato","year":"2020","journal-title":"J Immunol."},{"key":"2025112507284084600_bib13","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J Clin Invest"},{"key":"2025112507284084600_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","article-title":"Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells","volume":"33","author":"Inozume","year":"2010","journal-title":"J Immunother"},{"key":"2025112507284084600_bib15","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"2025112507284084600_bib16","doi-asserted-by":"crossref","first-page":"e122467","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"2025112507284084600_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"2025112507284084600_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"2025112507284084600_bib19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2025112507284084600_bib20","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112507284084600_bib21","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Ribas A, investigators K-. Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2025112507284084600_bib22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"2025112507284084600_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of ipilimumab and adoptive cell therapy with Tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front Oncol"},{"key":"2025112507284084600_bib24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"2025112507284084600_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"key":"2025112507284084600_bib26","doi-asserted-by":"crossref","first-page":"P49","DOI":"10.1186\/2051-1426-3-S2-P49","article-title":"Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma","volume":"3","author":"Sarnaik","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2025112507284084600_bib27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of Tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025112507284084600_bib28","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"2025112507284084600_bib29","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112507284084600_bib30","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112507284084600_bib31","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"key":"2025112507284084600_bib32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"2025112507284084600_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Investigators R-. relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112507284084600_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","article-title":"Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression","volume":"28","author":"Huang","year":"2005","journal-title":"J Immunother"},{"key":"2025112507284084600_bib35","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib36","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025112507284084600_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"2025112507284084600_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"2025112507284084600_bib39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2025112507284084600_bib40","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2025112507284084600_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"2025112507284084600_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.immuni.2020.07.007","article-title":"Adoptive T cell therapy targeting different gene products reveals diverse and Context-dependent immune evasion in melanoma","volume":"53","author":"Effern","year":"2020","journal-title":"Immunity"},{"key":"2025112507284084600_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-22-2103\/3213221\/ccr-22-2103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-22-2103\/3219939\/ccr-22-2103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/28\/24\/5317\/3229207\/5317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/28\/24\/5317\/3229207\/5317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:29:03Z","timestamp":1764073743000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/28\/24\/5317\/711447\/Combination-Nivolumab-CD137-Agonism-and-Adoptive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":43,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,10,10]]},"published-print":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-2103","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22488848.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6532817.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488839.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488845.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488842.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6532817","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488851.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22488842","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.30705789","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.30705795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.30705783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.30705792","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.30705786","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]}}}